You just read:

Actelion Submits Supplemental New Drug Application to US FDA Seeking Approval of OPSUMIT® (macitentan) for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

News provided by

Actelion Ltd.

Apr 30, 2018, 09:00 ET